attached to avoid abandonment underovisions of 37 CFR 1.136(a)). the nucleotide and/or amino acid seque requirements for such a disclosure 1. This application clearly fails to content attention is directed to the final rule	below within the time period ser 35 U.S.C. § 133 (extension uence disclosure contained in as set forth in 37 C.F.R. 1.82 comply with the requirements of	set the Office action to which the Notice as of time may be obtained under the this application does not comply with 21 - 1.825 for the following reason(s):
pplicant must file the items indicated attached to avoid abandonment underovisions of 37 CFR 1.136(a)). the nucleotide and/or amino acid seque requirements for such a disclosure 1. This application clearly fails to content attention is directed to the final rule	Bridget E. Bunner EQUIREMENTS FOR PA EQUENCE AND/OR AM below within the time period s er 35 U.S.C. § 133 (extension uence disclosure contained in as set forth in 37 C.F.R. 1.82 comply with the requirements of	set the Office action to which the Notice as of time may be obtained under the this application does not comply with 21 - 1.825 for the following reason(s):
pplicant must file the items indicated attached to avoid abandonment underovisions of 37 CFR 1.136(a)). the nucleotide and/or amino acid sequence requirements for such a disclosure. 1. This application clearly fails to contact a directed to the final rule.	below within the time period ser 35 U.S.C. § 133 (extension as set forth in 37 C.F.R. 1.82)	set the Office action to which the Notice as of time may be obtained under the this application does not comply with 21 - 1.825 for the following reason(s):
pplicant must file the items indicated attached to avoid abandonment underovisions of 37 CFR 1.136(a)). the nucleotide and/or amino acid sequence requirements for such a disclosure. 1. This application clearly fails to contact a directed to the final rule.	below within the time period ser 35 U.S.C. § 133 (extension as set forth in 37 C.F.R. 1.82)	set the Office action to which the Notice as of time may be obtained under the this application does not comply with 21 - 1.825 for the following reason(s):
pplicant must file the items indicated a attached to avoid abandonment underovisions of 37 CFR 1.136(a)). the nucleotide and/or amino acid seque requirements for such a disclosure 1. This application clearly fails to content attention is directed to the final rule.	below within the time period ser 35 U.S.C. § 133 (extension uence disclosure contained in as set forth in 37 C.F.R. 1.82 comply with the requirements of	set the Office action to which the Notice as of time may be obtained under the this application does not comply with 21 - 1.825 for the following reason(s):
attached to avoid abandonment underovisions of 37 CFR 1.136(a)). the nucleotide and/or amino acid seque requirements for such a disclosure 1. This application clearly fails to content attention is directed to the final rule	er 35 U.S.C. § 133 (extension uence disclosure contained in as set forth in 37 C.F.R. 1.82 comply with the requirements of	set the Office action to which the Notice as of time may be obtained under the this application does not comply with 21 - 1.825 for the following reason(s):
ne requirements for such a disclosure 1. This application clearly fails to content attention is directed to the final rule	as set forth in 37 C.F.R. 1.82 omply with the requirements of	21 - 1.825 for the following reason(s):
attention is directed to the final rule	omply with the requirements o	of 37 C.F.R. 1.821-1.825 Applicant's
notice published at 63 FR 29620 (J	ctive filing date is on or after J	5 FR 18230 (May 1, 1990), and 1114 uly 1, 1998, see the final rulemaking
2. This application does not contain Listing" as required by 37 C.F.R. 1	n, as a separate part of the di .821(c).	sclosure on paper copy, a "Sequence
3. A copy of the "Sequence Listing" 37 C.F.R. 1.821(e).	" in computer readable form h	nas not been submitted as required by
4. A copy of the "Sequence Listing content of the computer readable for 1.823, as indicated on the attached."	form does not comply with the	requirements of 37 C.F.R. 1.822 and/or
 The computer readable form the and/or unreadable as indicated on readable form must be submitted a 	the attached CRF Diskette P	olication has been found to be damaged roblem Report. A Substitute computer 5(d).
6. The paper copy of the "Sequence "Sequence Listing" as required by	ce Listing" is not the same as 37 C.F.R. 1.821(e).	the computer readable from of the
7. Other:		
Applicant Must Provide: ☑ An initial or substitute computer rea	adable form (CRF) copy of th	e "Sequence Listing".
An initial or substitute paper copy onto the specification.	of the "Sequence Listing", as	well as an amendment directing its entry
A statement that the content of applicable, include no new matter, as .825(d).	the paper and computer rearrequired by 37 C.F.R. 1.821	adable copies are the same and, where (e) or 1.821(f) or 1.821(g) or 1.825(b) or
For questions regarding complia	ance to these requiremen	nts, please contact:
For Rules Interpretation, call (70 For CRF Submission Help, call	(703) 308-4212	
PatentIn Software Program Sup Technical Assistance To Purchase PatentIn Softv	703-2	

16-14-01

Express Mail Label No. EK611905193US Date of Deposit: June 13, 2001

PATENT APPLICATION

Attorney Docket No.: 00960-569 (CBM-69)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS:

Charette et al.

ASSIGNEE:

Creative Biomolecules, Inc.

SERIAL NUMBER:

09/509,648

EXAMINER:

B. Bunner

FILING DATE:

October 5, 2000

ART UNIT:

1647

TECH CENTER 1600/2900

FOR: ENHANCEMENT OF MORPHOGEN ACTIVITY

June 13, 2001

Boston, Massachusetts

BOX SEQUENCE LISTING

Assistant Commissioner for Patents Washington, D.C. 20231

TRANSMITTAL LETTER

Applicants are filing herewith a response to the Office communication containing the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures mailed May 24, 2001, which is due on or before June 23, 2001. Enclosed herewith are the following for the above-identified non-provisional patent application:

 \boxtimes Response to Office communication containing the Notice to Comply with Sequence Listing Requirement (2) pages);

 \bowtie Copy of Notice to Comply with Sequence Listing Requirements (1 page);

 \boxtimes Initial Computer Readable Form Copy of the "Sequence Listing" (1 diskette);

 \boxtimes Paper Copy of the "Sequence Listing" (10 pages);

 \boxtimes Statement in Support of Computer Readable Form Submission (1 page); and

 \boxtimes Postcard.

The Commissioner is hereby authorized to charge any fee that may be due, or to credit any overpayment, to Deposit Account No. 50-0311 (Reference No. 00960-569, CBM-69). A duplicate copy of this transmittal letter is enclosed.

Respectfully submitted

or R. Elriff, Reg. No. 39,

Barry J. Marenberg, Reg. No. 40,715

Attorneys for Applicants c/o MINTZ, LEVIN

One Financial Center

Boston, Massachusetts 02111

Tel: (617) 542-6000 Fax: (617) 542-2241

TRA 1528781v1